EOLS

Evolus

Stock NASDAQ – Stock Market Prices, News & Analysis

Evolus Inc specializes in non-surgical aesthetic products for anti-aging and facial rejuvenation applications.

$ 4.03
6.50 %

Evolus

$ 4.03
6.50 %
EOLS

Evolus Inc specializes in non-surgical aesthetic products for anti-aging and facial rejuvenation applications.

Price history of Evolus
Price history of Evolus

Performance & Momentum

6 Months 33.63 %
1 Year 66.71 %
3 Years 51.55 %
5 Years 67.63 %

Strategic Analysis

Evolus • 2026

Evolus Inc positions itself as a specialist in non-surgical aesthetic products, targeting a growing segment related to the global demand for anti-aging solutions. The company focuses on innovation and effective marketing of its treatments to attract clientele seeking less invasive alternatives to aesthetic surgery.

Strengths
  • Specialized niche in innovative and non-invasive aesthetic products
  • Growth potential supported by demographic and societal trends related to anti-aging
Weaknesses
  • Significant decline in stock performance over several years, indicating a fragile strategic or operational positioning
  • Uncertainty regarding the achievement of financial objectives, as evidenced by the recent downward revision despite favorable external advice
Momentum

Evolus's momentum is currently weak, reflected by a prolonged downward trend over multiple time horizons. The recent downward revision of commercial objectives, despite positive external consensus, highlights increased caution regarding its ability to regain traction in the medium term. This situation calls for heightened vigilance regarding operational and financial prospects in a competitive sector under strong pressure for innovation.

Analysis performed 1 month ago

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone